Highlights of This Issue 5831

SPECIAL FEATURES

Editorial

Gauging Progress in a Decades-Old Fight
Jesse Potash and Kenneth C. Anderson

CCR Translations

Model T Muscle CARs Can Treat Brain Tumors
Laura A. Johnson
See article p. 5949

CCR New Strategies

New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Katherine A. Janeway and Robert G. Maki

CCR Perspectives in Drug Approval

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

Molecular Pathways

Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival
Patrick T. Reilly and Tak W. Mak

Review

The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Brian M. Slomovitz and Robert L. Coleman

HUMAN CANCER BIOLOGY

Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas

Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas

Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells
Shahriar Koochekpour, Sunipa Majumdar, Gissou Azadabakhsh, Kristopher Attwood, Ray Scioneaux, Dhatchayani Subramani, Charles Manhardt, Giovanni D. Lorusso, Stacey S. Willard, Hillary Thompson, Mojgan Shourideh, Katayoon Rezaei, Oliver Sartor, James L. Mohler, and Robert L. Vessella

Expression of Serotonin Receptors in Human Hepatocellular Cancer
Christopher Soll, Marc-Oliver Rieker, Christian Eugen Oberkofler, Claus Hackerbrand, Peter J. Wild, Michelle L. DeOliveira, and Pierre-Alain Clavien
### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5911</td>
<td>Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo</td>
<td>Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Isuldinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, and Joyce M. Slingerland</td>
</tr>
<tr>
<td>5924</td>
<td>Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status</td>
<td>Maria Joao Baptista, Ana Muntanaola, Eva Calpe, Pau Abrquiseta, Olga Salamero, Eva Fernandez, Carlles Codony, Eva Giné, Susana G. Kalko, Marta Crespo, and Francesc Bosch</td>
</tr>
<tr>
<td>5934</td>
<td>Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vitro Antitumor Activity</td>
<td>Seong-Hoon Yun, Eun-Seon Park, Sung-Won Shin, Yong-Woo Na, Jin-Yesung Han, Jin-Sook Jeong, Valeria V. Shastina, Valentin A. Stonik, Joo-In Park, and Jong-Young Kwak</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6011</td>
<td>FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51</td>
<td>Nu Zhang, Xinjian Wu, Lixuan Yang, Feizhe Xiao, Heng Zhang, Aidong Zhou, Zhengqiong Huang, and Suyun Huang</td>
</tr>
<tr>
<td>6001</td>
<td>ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients</td>
<td>Anita Sveen, Trude H. Aagesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestøl, Rolf I. Skotheim, and Ragnhild A. Lothe</td>
</tr>
<tr>
<td>6011</td>
<td>A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children’s Oncology Group Phase I Consortium Report</td>
<td>Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Sterpak, Frank M. Balis, and Susan M. Blaney</td>
</tr>
</tbody>
</table>

### IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5972</td>
<td>Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer</td>
<td>Dharamna Madhavan, Manuela Zechacker, Markus Wallwiener, Karatina Cuk, Caroline Modugno, Martina Scharpf, Sarah Schott, Jörg Heil, Andrei Turchinovich, Rongyi Yang, Axel Benner, Sabine Rietdorph, Andreas Triumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel</td>
</tr>
<tr>
<td>5983</td>
<td>Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study</td>
<td>Xia Pu, Yuanqing Ye, Margaret R. Spitz, Liang Wang, Jian Gu, Scott M. Lippman, Michelle A.T. Hildebrandt, Waun Ki Hong, John D. Minna, Jack A. Roth, Ping Yang, and Xifeng Wu</td>
</tr>
<tr>
<td>5992</td>
<td>Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer</td>
<td>Masanori Terashima, Koji Kitada, Atsushi Ochiai, Wataru Ichikawa, Issei Kurohashi, Shinichi Sakuramoto, Hitoshi Katai, Takeshi Sano, Hiroshi Imamura, and Mitsuhiro Sasaki; for the ACTS-GC Group</td>
</tr>
</tbody>
</table>

**American Association for Cancer Research**

Clinical Cancer Research

Downloaded from clincancerres.aacrjournals.org on December 31, 2017. © 2012 American Association for Cancer Research.
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, and Priti S. Hegde

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jagg, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droega, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, and Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)

Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children’s Oncology Group Phase I Consortium Study
Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, and Susan M. Blaney

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaugnessy Jr, Bart Barlogie, and John Crowley

Spleen Cells from Young Donors Eradicate Large Tumors—Letter
Laszlo Radvanyi

Spleen Cells from Young Donors Eradicate Large Tumors—Response
Donald A. Rowley, Karin Schreiber, and Hans Schreiber

Bioluminescence Imaging of Prenylation Inhibition—Letter
Philippe Clezardin

Bioluminescence Imaging of Prenylation Inhibition—Response
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms

Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
ABOUT THE COVER

Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue.